Drug Trial Radar · NCT01103323
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Last checked: Nov 19, 2026Latest source record: Jun 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
760
Actual
Start
Apr 2010
Primary completion
Jul 2011
Study completion Jan 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Apr 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC
Conditions
- Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506)Drug
160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
PlaceboDrug
matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Best Supportive Care (BSC)Other
BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).
Locations
171 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Mission Hills, California
Site not named
Orange, California
Site not named
Redlands, California
Site not named
Santa Maria, California
Site not named
Aventura, Florida
Site not named
Jacksonville, Florida
Site not named
Peoria, Illinois
Site not named
Cedar Rapids, Iowa
Site not named
New Orleans, Louisiana
Site not named
Ann Arbor, Michigan
Site not named
Rochester, Minnesota
Site not named
Saint Cloud, Minnesota
Site not named
Jefferson City, Missouri
Site not named
Neptune City, New Jersey
Site not named
New York, New York
Site not named
Fargo, North Dakota
Site not named
Toledo, Ohio
Site not named
Scranton, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Sumter, South Carolina
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Green Bay, Wisconsin
Site not named
Capital Federal-Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
San Miguel de Tucumán, Tucumán Province, Argentina
Site not named
Concord, New South Wales, Australia
Site not named
St Leonards, New South Wales, Australia
Site not named
Woolloogabba, Queensland, Australia
Site not named
Woodville South, South Australia, Australia
Site not named
Footscray, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Bruxelles - Brussel, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Bruxelles - Brussel, Belgium
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.